Edesa Biotech 미래 성장
Future 기준 확인 0/6
Edesa Biotech's earnings are forecast to decline at 32.7% per annum. EPS is expected to grow by 16.6% per annum.
주요 정보
-32.7%
수익 성장률
16.6%
EPS 성장률
Biotechs 수익 성장 | 27.1% |
매출 성장률 | n/a |
향후 자기자본 수익률 | n/a |
애널리스트 커버리지 | Low |
마지막 업데이트 | 20 Aug 2024 |
최근 미래 성장 업데이트
Recent updates
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely
Aug 04We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate
Mar 10Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%
Sep 30Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Sep 23Edesa says mid-stage trial for anti-allergic cream reached full enrollment
Sep 07Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Aug 12Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
May 16Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Apr 18Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Dec 08Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
Sep 22Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Aug 27Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study
Jun 18Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?
Apr 13Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)
Feb 19Edesa Biotech receives C$14M for COVID-19 study
Feb 02Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Dec 08Edesa Biotech EPS misses by $0.04, beats on revenue
Dec 07Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment
Nov 03수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
9/30/2026 | N/A | -14 | N/A | N/A | 1 |
9/30/2025 | N/A | -11 | N/A | N/A | 2 |
9/30/2024 | N/A | -8 | N/A | N/A | 2 |
6/30/2024 | N/A | -7 | -5 | -5 | N/A |
3/31/2024 | N/A | -7 | -6 | -6 | N/A |
12/31/2023 | N/A | -8 | -6 | -6 | N/A |
9/30/2023 | N/A | -8 | -7 | -7 | N/A |
6/30/2023 | N/A | -9 | -11 | -11 | N/A |
3/31/2023 | N/A | -13 | -12 | -12 | N/A |
12/31/2022 | N/A | -16 | -11 | -11 | N/A |
9/30/2022 | N/A | -18 | -12 | -12 | N/A |
6/30/2022 | N/A | -18 | -7 | -7 | N/A |
3/31/2022 | N/A | -17 | -7 | -7 | N/A |
12/31/2021 | N/A | -15 | -14 | -14 | N/A |
9/30/2021 | N/A | -13 | -14 | -14 | N/A |
6/30/2021 | 0 | -12 | -15 | -15 | N/A |
3/31/2021 | 0 | -9 | -13 | -13 | N/A |
12/31/2020 | 0 | -8 | -7 | -7 | N/A |
9/30/2020 | 0 | -6 | -5 | -5 | N/A |
6/30/2020 | 1 | -5 | -5 | -5 | N/A |
3/31/2020 | 1 | -5 | -6 | -6 | N/A |
12/31/2019 | 1 | -4 | -6 | -6 | N/A |
9/30/2019 | 0 | -3 | -5 | -5 | N/A |
6/30/2019 | 0 | -3 | -4 | -4 | N/A |
3/31/2019 | N/A | -2 | -1 | -1 | N/A |
12/31/2018 | N/A | -2 | -1 | -1 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: EDSA is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: EDSA is forecast to remain unprofitable over the next 3 years.
고성장 수익: EDSA is forecast to remain unprofitable over the next 3 years.
수익 대 시장: Insufficient data to determine if EDSA's revenue is forecast to grow faster than the US market.
고성장 수익: EDSA is forecast to have no revenue next year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if EDSA's Return on Equity is forecast to be high in 3 years time